Results 111 to 120 of about 66,826 (280)

Pyoderma Gangrenosum in a Patient with Crohn’s Disease Treated with Adalimumab: A Case-Based Review and Systematic Review of the Current Literature

Clinics and Practice
Background: Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that frequently occurs in association with systemic diseases such as inflammatory bowel disease (IBD).
Fotios S. Fousekis, Konstantinos Mpakogiannis, Emmanouil Karampinis, Ioanna Nefeli Mastorogianni, Dimitrios K. Christodoulou, Marina Papoutsaki, Evanthia Zampeli, Konstantinos H. Katsanos   +7 more
doaj   +1 more source

Use of biological drugs in patients with psoriasis and psoriatic arthritis in italy: Results from the PSONG survey [PDF]

, 2018
This Italian multicenter retrospective study compared the drug survival and efficacy of differentanti-TNF agents in psoriasis (PsO) and psoriatic arthritis (PsA) patients.
Berardesca, E, Bernardini, N, Bianchi, L, Chimenti, S, Costanzo, A., D'Epiro, S, De Simone, C, Narcisi, A, Orsini, D, Peris, K, Potenza, Mc, Richetta, A, Teoli, M, Zangrilli, A   +13 more
core  

A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies [PDF]

, 2020
With recent advancements in the understanding of vitiligo pathogenesis, Janus kinase (JAK) inhibitors have emerged as a promising new treatment modality, but their effects remain incompletely elucidated.
Alikhan, Mujahed, Jogi, Reena, Nguyen, Julie K, Patel, Anisha B, Schlichte, Megan J   +4 more
core  

Evaluating the impact of therapeutic drug monitoring strategies on clinical outcomes in paediatric inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives The increasing incidence of inflammatory bowel disease (IBD) in paediatric populations underscores the importance of effective management strategies. Anti–tumor necrosis factor (anti‐TNF) agents, such as infliximab (IFX) and adalimumab (ADL), are key treatments for inducing and maintaining remission in IBD, but many patients ...
Karlotta Pauline Hubert, Sebastian Stricker, Jan De Laffolie   +2 more
wiley   +1 more source

Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis

Pharmaceuticals
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages ...
Wenting Zhang, Ziqi Xu, Yamin Shu, Sainan Shu, Qilin Zhang   +4 more
doaj   +1 more source

Long-Term Corticosteroid-Sparing Immunosuppression for Cardiac Sarcoidosis. [PDF]

, 2019
Background Long-term corticosteroid therapy is the standard of care for treatment of cardiac sarcoidosis (CS). The efficacy of long-term corticosteroid-sparing immunosuppression in CS is unknown.
Benn, Bryan S, De Marco, Teresa, Gerstenfeld, Edward P, Hsia, Henry H, Janmohamed, Munir, Klein, Liviu, Koth, Laura L, Lee, Byron K, Moss, Joshua D, Murray, Tyler O, Pampaloni, Miguel H, Parwani, Purvi, Petek, Bradley J, Rosenthal, David G, Scheinman, Melvin M, Selby, Van, Vedantham, Vasanth, Zikherman, Julie   +17 more
core  

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Adalimumab is commonly used to induce and maintain remission in pediatric Crohn's disease (CD). However, data on the efficacy and safety of high‐dose adalimumab in this population are limited. This study aimed to evaluate the therapeutic effectiveness and safety of weekly high‐dose adalimumab (80 mg) in pediatric CD patients ...
Eyal Cohen‐Sela, Anat Yerushalmy‐Feler, Firas Rinawi, Esther Orlanski‐Meyer, Raouf Nassar, Ramit Magen‐Rimon, Yael Weintraub, Raanan Shamir, Dror S. Shouval, Manar Matar   +9 more
wiley   +1 more source

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. [PDF]

, 2019
Tofacitinib is an oral Janus kinase inhibitor approved for the treatment of psoriatic arthritis (PsA). It provides an alternative option for patients who have had an inadequate response and tolerance to other disease modifying antirheumatic drugs (DMARDs)
Beck, Kristen M, Liao, Wilson, Ly, Karen, Orbai, Ana-Maria, Smith, Mary P   +4 more
core  

Upper and small bowel Crohn's disease in Brazilian children: Phenotypic characteristic and surgical risk

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Upper and small bowel Crohn's disease (U‐SBCD) represents a clinically aggressive phenotype with high complication rates yet remains diagnostically challenging. In low‐ and middle‐income countries (LMICs), limited inflammatory bowel disease (IBD) awareness contributes to diagnostic delays, but their impact on U‐SBCD outcomes remains
Jane Oba, Carlos Walter Sobrado, Elizete Aparecida Lomazi, Mariana Deboni, Michela Cynthia da Rocha Marmo, Vanessa Adriana Scheeffer, Silvio da Rocha Carvalho, Adérson Omar Mourão Cintra Damião, Matheus Freitas Cardoso de Azevedo, Carlos Frederico Sparapan Marques, Eytan Wine, Artur Figueiredo Delgado, Clovis Artur Almeida da Silva Full   +12 more
wiley   +1 more source

Defining medication adherence in individual patients

Patient Preference and Adherence, 2015
Alan Morrison, Melissa E Stauffer, Anna S Kaufman ScribCo, Effort, PA, USA Background: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken ...
Morrison A, Stauffer ME, Kaufman AS
doaj